, , , -
Both medications note the risk of delayed gastric emptying, among other stomach problems such as nausea, vomiting, and diarrhea, but do not include an explicit warning of gastroparesis
Compounded GLP-1 optionsincluding semaglutide and tirzepatidediffer in potency and titration flexibility, and biomarker profiles help align medication with your individual metabolic needs
Quarterly lab panels: A broad baseline followed by targeted follow-up testing, so dosing and protocol track your real biomarkers, not a generic schedule
Your doctor may have prescribed Tresiba because you have type 1 diabetes, your beta cells are no longer producing enough insulin for GLP-1 medications to be effective, you have contraindications to GLP-1 therapy, or your blood sugar requires the reliable, direct glucose-lowering that only exogenous insulin provides